MINERALYS THERAPEUTICS INC. - COMMON STOCK

14,65

09-мая-25 16:45:00

15 мин. задержка

Акции

-0,96

-6,15%

Сегодняшний диапазон

14,40 - 15,94

ISIN

N/A

Источник

NASDAQ

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

25 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference

28 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

13 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

05 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

14 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

03 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

06 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024

02 май 2024 08:00:01 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

21 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

13 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics Announces $120 Million Private Placement Financing

08 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

29 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

04 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

21 дек 2023 16:05:03 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

11 ноя 2023 11:30:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics to Participate in Three Upcoming Conferences

09 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 ноя 2023 16:05:02 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

02 ноя 2023 10:00:00 Источник Nasdaq GlobeNewswire
Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023

31 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.